Celldex Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; financial statements are unaudited. Celldex is a clinical-stage biopharmaceutical company focused on antibody therapies, including barzolvolimab. Unless noted otherwise, amounts below are in millions of dollars.
Financial results and position
- Revenue: $0.156 million, down 84% from $0.967 million in Q1 2023. Revenue was primarily from contract and grant activity; the filing reports no meaningful product sales.
- Operating expenses: $40.764 million, up 22% year over year. Research and development was $31.661 million (+18%); general and administrative was $9.103 million (+37%). Management attributed the increases primarily to expanded barzolvolimab development, higher personnel and stock-based compensation, and commercial planning.
- Loss: Operating loss was $40.608 million versus $32.471 million. Net loss was $32.808 million, compared with $29.361 million; net loss per share was $0.56 versus $0.62. Higher investment and other income partly offset higher operating costs.
- Cash flow: Cash used in operating activities was $40.638 million, versus $28.569 million in Q1 2023. Investing activities used $315.211 million, largely reflecting net purchases of marketable securities. Financing provided $436.112 million, primarily from the March stock offering.
- Liquidity: Cash and cash equivalents were $115.077 million and marketable securities were $708.769 million at March 31, totaling approximately $823.8 million, up from approximately $423.6 million at December 31, 2023. Management says resources are sufficient to fund planned operations through 2027; the filing also notes the future runway depends in part on the timing and form of a potential settlement milestone payment.
- Capital structure and liabilities: Celldex raised $432.3 million net by issuing 9,798,000 shares in March. Shares outstanding rose to 65,910,548 from 55,883,377 at year-end. Total liabilities were $30.234 million; the balance sheet does not report borrowings or other conventional debt.
- Margins: With very limited revenue and substantial clinical-stage expenses, operating and net margins are not useful indicators of commercial performance.
Material changes and outlook
- R&D spending increased $4.9 million, with barzolvolimab/anti-KIT program expense rising to $23.778 million from $17.683 million. Management expects operating cash use, R&D personnel costs, product development expenses, and G&A to increase over the next 12 months as development and commercial planning expand.
- Management expects contract and grant revenue to increase over the next 12 months, primarily due to anticipated services under agreements with Rockefeller University. Investment income is expected to remain relatively consistent, subject to quarterly fluctuation.
- Celldex plans to initiate two Phase 3 CSU studies in summer 2024 and expects to report 52-week CSU and Phase 2 chronic inducible urticaria data in the second half of 2024. It initiated a Phase 2 prurigo nodularis study in April 2024; enrollment in the Phase 2 EoE study is ongoing. Enrollment is also ongoing in the Phase 1 CDX-585 solid-tumor study.
- Q1 results included $7.8 million of investment and other income, up from $3.1 million, which management attributed primarily to higher cash balances following equity offerings. The company also recorded a $1.064 million unrealized loss on marketable securities in other comprehensive income.
Risks, contingencies, and other considerations
- Celldex has recurring losses and depends on clinical and regulatory success; early-stage results may not predict later trial outcomes. Trials can be delayed, fail, or require greater resources than anticipated.
- Management believes available resources support planned operations through 2027, but cautions that longer-term funding may require partnering, licensing, debt, or additional equity. Financing may be unavailable or unfavorable, and equity issuance may dilute stockholders.
- Under a settlement related to the Kolltan acquisition, a $52.5 million payment is due upon the first qualifying FDA or EMA approval of a surviving company product. Celldex may elect to pay in cash, shares, or a combination. The filing says the payment could affect liquidity if the milestone is achieved.
- Marketable securities are investment grade; Celldex reported no credit-loss investments at quarter-end. It stated that interest-rate exposure was not material. No material changes to previously disclosed risk factors were reported.
- The filing describes an anaphylactic reaction in one patient in the earlier Phase 1b prurigo nodularis study; it resolved without sequelae. Reported clinical activity and safety findings remain subject to confirmation in larger and later-stage trials.
Key facts for investors to verify
- Progress, timing, and results of planned Phase 3 CSU trials and expected second-half 2024 CSU and CIndU data.
- Quarterly operating cash use and whether management’s stated runway through 2027 remains supportable as trial and commercial-planning expenses rise.
- Potential timing and payment form of the $52.5 million acquisition-settlement milestone, if triggered.
- Clinical efficacy and safety of barzolvolimab in larger, later-stage studies, including the significance of reported adverse events.
- Share-count changes, remaining ATM capacity, and the potential dilution from future equity financing or settlement payment in shares.